溶瘤生物科技 ONCY 深 滬
等待開盤 06-25 09:30:00 美东时间
0.9215
-0.019
-2.06%
華盛通- 最 高0.98
- 今 開0.9541
- 成交量 87.42万股
- 最 低 0.91
- 昨 收 0.9409
- 總市值 1.10亿
- 52周最高 1.51
- 市盈率 靜 --
- 換手率 0.73%
- 52周最低 0.77
- 委 比 -65.40%
- 總股本 1.19亿
- 歷史最高 6.037
- 量 比 0.59
- 振 幅 7.44%
- 歷史最低 0.3258
- 每 手 1
- 風險率 0.16%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Oncolytics Biotech Receives New U.S. Patent For Its Proprietary Manufacturing Process For Pelareorep
Oncolytics Biotech® Inc. (Nasdaq: ONCY) ("Oncolytics" or the "Company"), a clinical-stage company developing pelareorep, an investigational, systemically active immunotherapy that promotes potentially protective immune responses, including the upregulation of key inflammatory cytokines resulting in ...
06-16 21:02
Oncolytics Biotech® Secures New U.S. Patent Protecting Commercial Manufacturing of Pelareorep into 2044
Oncolytics Biotech Inc. announced that the USPTO has issued a new patent protecting its proprietary manufacturing process for pelareorep, providing intellectual property protection into 2044. The company also noted that a previously filed method-of-use patent application for pelareorep as an immunotherapy remains under review and, if issued, would provide protection into 2046. Additionally, Oncolytics plans to file further patent applications in ...
06-16 13:00
Oncolytics Biotech Promotes John McAdory To COO
Oncolytics Biotech® Inc. (NASDAQ:ONCY) ("Oncolytics" or the "Company"), a clinical-stage company developing pelareorep, an investigational, systemically active immunotherapy that promotes potentially protective
06-02 21:05
Oncolytics Highlights Pelareorep-RAS Combo Preclinical Cancer Results
Oncolytics Biotech ( ($ONCY) ) just unveiled an announcement. On June 1, 2026, ...
06-01 21:55
Oncolytics Biotech Announces Initial Data From Preclinical Study Supporting Further Evaluation Of Pelareorep In Combination With RAS Inhibitor Modalities In Solid Tumor Model
Oncolytics Biotech® Inc. (NASDAQ:ONCY) ("Oncolytics" or the "Company"), a clinical-stage company developing pelareorep, today announced initial data from a preclinical study evaluating pelareorep in combination with
06-01 21:08
Oncolytics Biotech® Announces Positive Initial Preclinical Findings Supporting Further Evaluation of Pelareorep in Combination with RAS-Targeted Approaches
Oncolytics Biotech announced initial data from a preclinical study showing enhanced anti-tumor activity when combining pelareorep with RAS inhibitors in a solid tumor model. The company plans additional studies in pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC) models to evaluate immune activation, tumor response durability, and resistance timing. Full results are expected in late 2026. Pelareorep, an investigational immunothe...
06-01 13:00
美股大行评级 | 市值直指1.8万亿美元？瑞银给出美光1600美元天价目标！华尔街绩前集体上调迈威尔科技目标价
今日重点评级关注：Canaccord Genuity：维持Dakota Gold"投机性买入"评级，目标价从16美元升至18美元；瑞杰金融：上调Tectonic Therapeutic评级至"强烈买入"，目标价从76美元升至81美元
05-27 17:33
Oncolytics Highlights Pelareorep Immune Activation Data at ASCO
Oncolytics Biotech ( ($ONCY) ) just unveiled an update. On May 22, 2026, Oncoly...
05-22 21:33
Oncolytics Biotech® to Present Data at ASCO 2026 Reinforcing Pelareorep’s Potential Across Gastrointestinal Tumors
Oncolytics Biotech announced translational data from the GOBLET and AWARE-1 trials showing that pelareorep, an investigational immunotherapy, induces both innate and adaptive antiviral and anti-tumor immune responses. The data, to be presented at the 2026 ASCO Annual Meeting, demonstrate pelareorep's ability to expand preexisting tumor-reactive immune cells, leading to tumor regression. In pancreatic cancer, pelareorep expanded anti-viral T cells...
05-22 13:00
Oncolytics Biotech Announces Its Data From REO 022 Trial In Metastatic Colorectal Cancer Shows 19.5-Month Median Duration Of Response In Second-Line KRAS-Mutant MSS mCRC Participants
Oncolytics Biotech® Inc. (NASDAQ:ONCY) ("Oncolytics" or the "Company"), a clinical-stage company developing pelareorep, an investigational, systemically delivered immunotherapy that has been shown to activate innate
05-04 21:02
